Cost-Effectiveness of Bedaquiline or Delamanid Plus Background Regimen for Multidrug-Resistant Tuberculosis in a High-Income Intermediate Burden City of China

International Journal of Infectious Diseases - Netherlands
doi 10.1016/j.ijid.2018.10.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China

PLoS ONE
Multidisciplinary
2013English

New Drugs to Treat Multidrug-Resistant Tuberculosis: The Case for Bedaquiline

Therapeutics and Clinical Risk Management
2014English

Bedaquiline and Multidrug-Resistant Tuberculosis: A Systematic and Critical Analysis of the Evidence

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2016English

Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2013English

Is Bedaquiline as Effective as Fluoroquinolones in the Treatment of Multidrug-Resistant Tuberculosis?

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2016English

Long-Term Impact of the Adoption of Bedaquiline-Containing Regimens on the Burden of Drug-Resistant Tuberculosis in China

BMC Infectious Diseases
Infectious Diseases
2020English

Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2016English

Transmission of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in a Metropolitan City

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy